Wolverine Trading’s GoodRx Holdings GDRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$85.4K Buy
19,900
+5,900
+42% +$25.9K ﹤0.01% 5254
2025
Q2
$68.6K Sell
14,000
-200
-1% -$869 ﹤0.01% 4266
2025
Q1
$63.9K Buy
14,200
+1,500
+12% +$7.04K ﹤0.01% 4362
2024
Q4
$57.3K Buy
+12,700
New +$69.8K ﹤0.01% 4949
2023
Q3
Sell
-12,500
Closed -$68.9K 4700
2023
Q2
$68.9K Buy
+12,500
New +$67.3K ﹤0.01% 3872
2023
Q1
Sell
-12,900
Closed -$60K 4485
2022
Q4
$60K Sell
12,900
-16,600
-56% -$81.8K ﹤0.01% 3537
2022
Q3
$142K Buy
+29,500
New +$186K ﹤0.01% 3775
2022
Q1
Sell
-71,400
Closed -$2.37M 5757
2021
Q4
$2.37M Sell
71,400
-58,900
-45% -$2.37M ﹤0.01% 1734
2021
Q3
$5.33M Buy
130,300
+31,900
+32% +$1.16M 0.01% 1252
2021
Q2
$3.55M Sell
98,400
-54,800
-36% -$2.02M 0.01% 1437
2021
Q1
$5.81M Buy
153,200
+86,200
+129% +$3.88M 0.01% 1011
2020
Q4
$2.83M Buy
+67,000
New +$3.08M ﹤0.01% 1447

Other funds holding GDRX

Wolverine Trading's GDRX Position: Q3 2025 in Review

Wolverine Trading reduced its GoodRx Holdings (GDRX) stake by 0.72% in Q3 2025, selling an estimated $422 and leaving 13,204 shares worth $56.6K. The position accounts for ﹤0.01% of the portfolio, ranked #5386.

Wolverine Trading first reported a position in GDRX in Q4 2020 and has held it in 9 quarters since. The position peaked at $1.56M in Q3 2021. 161 funds tracked by Wall St. Rank hold GDRX as of Q3 2025.

  • Wolverine Trading held 13,204 shares of GoodRx Holdings worth $56.6K as of Q3 2025.
  • Wolverine Trading sold 96 GoodRx Holdings shares in Q3 2025, an estimated $422.
  • GoodRx Holdings made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #5386 holding.
  • Wolverine Trading first reported a position in GoodRx Holdings in Q4 2020 and has held it in 9 quarters since.
  • Wolverine Trading's GoodRx Holdings position peaked at $1.56M in Q3 2021.
  • 161 funds tracked by Wall St. Rank held GoodRx Holdings as of Q3 2025.

Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.